Sun Fanglin, Pioneering Chinese Cancer Researcher Who Uncovered Pathways to Reverse Drug Resistance, Dies at 58
核心洞察
Leading Chinese biologist Sun Fanglin (搜索), director of the Advanced Institute of Translational Medicine at Tongji University (搜索), died on July 10 at age 58 after treatment for an undisclosed illness.
Sun's research focused on gene regulation and epigenetics in cellular aging and tumor formation, serving as chief scientist for multiple national research programs.
His team was the first globally to discover biological pathways capable of reversing tumor resistance to targeted drugs, a landmark breakthrough in oncology.
Leading Chinese biologist Sun Fanglin (搜索), whose groundbreaking research into cellular aging and tumor biology unlocked new avenues for overcoming drug resistance in cancer (搜索), died on July 10 at the age of 58. Sun had been receiving treatment for an undisclosed illness, according to an obituary posted by the Advanced Institute of Translational Medicine at Tongji University (搜索) in Shanghai, where he served as director.
Sun also held the position of former dean of Tongji University (搜索)'s School of Life Sciences and Technology. His career was defined by a deep investigation into how the aging process is shaped by gene regulation and epigenetics — the study of how behavior and environmental factors can alter gene function without changing the underlying DNA sequence.
A Career at the Forefront of Chinese Biomedical Research
Sun served as chief scientist for several national research programmes, including the National Programme on Key Basic Research, underscoring his stature within China's scientific community. His laboratory at Tongji University (搜索) became a hub for translational research aimed at bridging fundamental biological discoveries with clinical applications in oncology.
Reversing Drug Resistance: A World-First Breakthrough
Sun's most celebrated scientific achievement centered on one of oncology's most persistent challenges: tumor resistance to targeted therapies. His research team was the first in the world to crack this problem by identifying biological pathways capable of reversing the process by which tumors become resistant to targeted drugs.
The obituary issued by his institute noted that this breakthrough "provided a core theoretical framework for cell therapies and the development of new anti-tumour drugs." By elucidating the mechanisms through which cancer (搜索) cells evade pharmacological intervention, Sun's work opened the door to next-generation therapeutic strategies designed to restore drug sensitivity in previously resistant malignancies.
Legacy in Translational Medicine
Sun's contributions extend beyond his own laboratory. Through his leadership at the Advanced Institute of Translational Medicine, he helped shape an institutional culture focused on moving discoveries from bench to bedside. His work on epigenetics and gene regulation continues to inform ongoing efforts to develop more durable cancer (搜索) treatments that can circumvent the emergence of resistance — a problem that limits the long-term effectiveness of many precision oncology agents.
Sun Fanglin (搜索) is survived by colleagues and trainees whose work carries forward the theoretical and experimental foundations he established in the fight against cancer (搜索).